Blackstone Life Sciences Announces $455M Collaboration for Boston Scientific Heart Pump
FROM THE WIRE · FINANCE.YAHOO.COM
CAMBRIDGE, Mass., November 02, 2026--(BUSINESS WIRE)--Blackstone Life Sciences ("BXLS") today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA $455M co-funding deal for a cardiovascular product development is relevant for Boston Scientific.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Blackstone Life Sciences will co-fund development of the VITALYST system with Boston Scientific for $455 million.
- 02The device is a miniature heart pump for cardiogenic shock caused by acute heart attack.
- 03This is the first time Boston Scientific and BXLS will co-fund development of a Boston Scientific product.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Boston Scientific Corporation44.32 USDMarket closedtoday +5.57%Positive Blackstone Inc.120.16 USDMarket closedtoday +2.36%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets